ReviewFrontiers in endocrinology2026
Cellular senescence and metabolic aging in type 2 diabetes: mechanistic insights and translational implications.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is traditionally conceptualized as a disorder of insulin resistance and β-cell dysfunction driven by metabolic overload. Increasing evidence now implicates cellular senescence-a stress-induced state of durable cell-cycle arrest accompanied by a pro-inflammatory senescence-associated secretory phenotype (SASP)-as a biologically distinct contributor to metabolic dysfunction. Senolytic therapies, which selectively eliminate senescent cells by targeting senescent cell anti-apoptotic pathways (SCAPs), have therefore emerged as potential disease-modifying interventions. Methods: We conducted a structured narrative review of preclinical and human studies published between 2010 and 2025, identified through PubMed, Scopus, and Embase. Evidence was synthesized qualitatively, with emphasis on mechanistic plausibility, tissue specificity, translational readiness, and safety considerations relevant to T2DM and its complications. Results: Preclinical studies consistently demonstrate that clearance of senescent cells in adipose tissue, liver, and pancreatic islets improves insulin sensitivity, attenuates SASP-mediated inflammation, and preserves β-cell function across multiple diabetic models. Human evidence remains limited to small, short-duration pilot studies primarily designed to assess biological target engagement and short-term safety. These studies report reductions in senescence markers and inflammatory mediators following intermittent senolytic exposure, but lack standardized metabolic endpoints and long-term follow-up. Conclusion: Senolytic therapy represents a biologically compelling yet still experimental strategy for addressing the intersection of metabolic dysfunction and biological aging in T2DM. By reframing T2DM as a disease of metabolic aging, this review positions cellular senescence as an upstream therapeutic target and provides a conceptual framework to guide future precision-based clinical trials, rather than advocating near-term clinical adoption. By integrating geroscience with diabetology, this review positions cellular senescence as a biologically upstream framework that may inform future precision-based and disease-modifying strategies in type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.